collection
https://read.qxmd.com/read/32238419/acute-recurrent-pericarditis-from-pathophysiology-towards-new-treatment-strategy
#1
REVIEW
Patrice Cacoub, Cindy Marques
Acute idiopathic or so-called viral pericarditis is a frequent and usually benign disease, although recurrences are frequent. Data strongly suggest the presence of underlying autoinflammatory and/or autoimmune disorders. It has been reported that there is an inflammatory response of the innate immune system typical of 'autoinflammatory diseases', predominantly mediated by interleukin-1 (IL-1). This may result from the activation of the inflammasome by a cardiotropic virus or a non-specific agent. The inflammatory response of the adaptive immune system, typical of 'autoimmune diseases'-mainly mediated by autoantibodies or autoreactive T lymphocytes-seems also involved as anti-heart or anti-intercalated disk autoantibodies were associated with a higher number of recurrences and hospitalisations...
July 2020: Heart
https://read.qxmd.com/read/29281086/characteristics-of-patients-with-atrial-fibrillation-prescribed-antiplatelet-monotherapy-compared-with-those-on-anticoagulants-insights-from-the-garfield-af-registry
#2
JOURNAL ARTICLE
Freek W A Verheugt, Haiyan Gao, Wael Al Mahmeed, Giuseppe Ambrosio, Pantep Angchaisuksiri, Dan Atar, Jean-Pierre Bassand, A John Camm, Frank Cools, John Eikelboom, Gloria Kayani, Toon Wei Lim, Frank Misselwitz, Karen S Pieper, Martin van Eickels, Ajay K Kakkar
AIMS: Current atrial fibrillation (AF) guidelines discourage antiplatelet (AP) monotherapy as alternative to anticoagulants (ACs). Why AP only is still used is largely unknown. METHODS AND RESULTS: Factors associated with AP monotherapy prescription were analysed in GARFIELD-AF, a registry of patients with newly diagnosed (≤6 weeks) AF and ≥1 investigator-determined stroke risk factor. We analysed 51 270 patients from 35 countries enrolled into five sequential cohorts between 2010 and 2016...
February 7, 2018: European Heart Journal
https://read.qxmd.com/read/31504452/how-to-diagnose-heart-failure-with-preserved-ejection-fraction-the-hfa-peff-diagnostic-algorithm-a-consensus-recommendation-from-the-heart-failure-association-hfa-of-the-european-society-of-cardiology-esc
#3
JOURNAL ARTICLE
Burkert Pieske, Carsten Tschöpe, Rudolf A de Boer, Alan G Fraser, Stefan D Anker, Erwan Donal, Frank Edelmann, Michael Fu, Marco Guazzi, Carolyn S P Lam, Patrizio Lancellotti, Vojtech Melenovsky, Daniel A Morris, Eike Nagel, Elisabeth Pieske-Kraigher, Piotr Ponikowski, Scott D Solomon, Ramachandran S Vasan, Frans H Rutten, Adriaan A Voors, Frank Ruschitzka, Walter J Paulus, Petar Seferovic, Gerasimos Filippatos
Making a firm diagnosis of chronic heart failure with preserved ejection fraction (HFpEF) remains a challenge. We recommend a new stepwise diagnostic process, the 'HFA-PEFF diagnostic algorithm'. Step 1 (P=Pre-test assessment) is typically performed in the ambulatory setting and includes assessment for HF symptoms and signs, typical clinical demographics (obesity, hypertension, diabetes mellitus, elderly, atrial fibrillation), and diagnostic laboratory tests, electrocardiogram, and echocardiography. In the absence of overt non-cardiac causes of breathlessness, HFpEF can be suspected if there is a normal left ventricular ejection fraction, no significant heart valve disease or cardiac ischaemia, and at least one typical risk factor...
August 31, 2019: European Heart Journal
https://read.qxmd.com/read/28049699/on-treatment-blood-pressure-and-cardiovascular-outcomes-in-older-adults-with-isolated-systolic-hypertension
#4
RANDOMIZED CONTROLLED TRIAL
Yuichiro Yano, Hiromi Rakugi, George L Bakris, Donald M Lloyd-Jones, Suzanne Oparil, Takao Saruta, Kazuyuki Shimada, Hiroaki Matsuoka, Yutaka Imai, Toshio Ogihara
UNLABELLED: Our aim was to assess optimal on-treatment blood pressure (BP) at which cardiovascular disease (CVD) and all-cause mortality risks are minimized in Japanese older adults with isolated systolic hypertension. We used data from the VALISH study (Valsartan in Elderly Isolated Systolic Hypertension) that recruited older adults (n=3035; mean age, 76 years) with systolic BP (SBP) of ≥160 mm Hg and diastolic BP of <90 mm Hg. Patients were treated by valsartan...
February 2017: Hypertension
https://read.qxmd.com/read/31180747/the-qt-interval
#5
JOURNAL ARTICLE
John R Giudicessi, Peter A Noseworthy, Michael J Ackerman
No abstract text is available yet for this article.
June 11, 2019: Circulation
https://read.qxmd.com/read/30989614/new-mineralocorticoid-receptor-antagonists-update-on-their-use-in-chronic-kidney-disease-and-heart-failure
#6
REVIEW
Irene Capelli, Lorenzo Gasperoni, Marco Ruggeri, Gabriele Donati, Olga Baraldi, Giovanni Sorrenti, Maria Turchese Caletti, Valeria Aiello, Giuseppe Cianciolo, Gaetano La Manna
Aldosterone is a mineralocorticoid hormone with a well-known effect on the renal tubule leading to water retention and potassium reabsorption. Other major effects of the hormone include the induction of proinflammatory activity that leads to progressive fibrotic damage of the target organs, heart and kidney. Blocking the aldosterone receptor therefore represents an important pharmacological strategy to avoid the clinical conditions deriving from heart failure (CHF) and chronic kidney disease (CKD). However, steroidal mineralocorticoid receptor antagonists (MRA) have a low safety profile, especially in CKD patients due to the high incidence of hyperkalemia...
February 2020: Journal of Nephrology
https://read.qxmd.com/read/30742582/heart-failure-guidelines-what-you-need-to-know-about-the-2017-focused-update
#7
REVIEW
Lee Rodney Haselhuhn, Daniel J Brotman, Ilan Shor Wittstein
The 2017 focused update of the 2013 ACC/AHA guideline on heart failure contains new and important recommendations on prevention, novel biomarker uses, heart failure with preserved ejection fraction (HFpEF), and comorbidities such as hypertension, iron deficiency, and sleep-disordered breathing. Potential implications for management of acute decompensated heart failure will also be explored.
February 2019: Cleveland Clinic Journal of Medicine
https://read.qxmd.com/read/30509695/stroke-heart-syndrome-clinical-presentation-and-underlying-mechanisms
#8
REVIEW
Jan F Scheitz, Christian H Nolte, Wolfram Doehner, Vladimir Hachinski, Matthias Endres
Cardiac complications are a frequent medical problem during the first few days after an ischaemic stroke, and patients present with a broad range of symptoms including myocardial injury, cardiac dysfunction, and arrhythmia, with varying overlap between these three conditions. Evidence from clinical and neuroimaging studies and animal research suggests that these cardiac disturbances share the same underlying mechanisms. Although the exact cascade of events has yet to be elucidated, stroke-induced functional and structural alterations in the central autonomic network, with subsequent dysregulation of normal neural cardiac control, are the assumed pathophysiology...
December 2018: Lancet Neurology
https://read.qxmd.com/read/30272503/management-of-malignant-pleural-effusions-an-official-ats-sts-str-clinical-practice-guideline
#9
JOURNAL ARTICLE
David J Feller-Kopman, Chakravarthy B Reddy, Malcolm M DeCamp, Rebecca L Diekemper, Michael K Gould, Travis Henry, Narayan P Iyer, Y C Gary Lee, Sandra Z Lewis, Nick A Maskell, Najib M Rahman, Daniel H Sterman, Momen M Wahidi, Alex A Balekian
BACKGROUND: This Guideline, a collaborative effort from the American Thoracic Society, Society of Thoracic Surgeons, and Society of Thoracic Radiology, aims to provide evidence-based recommendations to guide contemporary management of patients with a malignant pleural effusion (MPE). METHODS: A multidisciplinary panel developed seven questions using the PICO (Population, Intervention, Comparator, and Outcomes) format. The GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach and the Evidence to Decision framework was applied to each question...
October 1, 2018: American Journal of Respiratory and Critical Care Medicine
https://read.qxmd.com/read/25854636/stroke-prevention-with-rivaroxaban-in-higher-risk-populations-with-atrial-fibrillation
#10
REVIEW
H-C Diener, J L Halperin, K Fox, G J Hankey
BACKGROUND: Atrial fibrillation (AF), the most common cardiac arrhythmia, is a major risk factor for stroke. Rivaroxaban, an oral factor Xa inhibitor, is approved for the prevention of stroke in patients with non-valvular AF. In the pivotal phase III trial ROCKET AF, rivaroxaban demonstrated non-inferiority compared with warfarin for reducing the risk of stroke or systemic embolism (SE) in patients with AF (intention-to-treat analysis), without an increased risk of major bleeding. Superior efficacy vs...
July 2015: International Journal of Clinical Practice
https://read.qxmd.com/read/30165632/2018-esc-eacts-guidelines-on-myocardial-revascularization
#11
REVIEW
Miguel Sousa-Uva, Franz-Josef Neumann, Anders Ahlsson, Fernando Alfonso, Adrian P Banning, Umberto Benedetto, Robert A Byrne, Jean-Philippe Collet, Volkmar Falk, Stuart J Head, Peter Jüni, Adnan Kastrati, Akos Koller, Steen D Kristensen, Josef Niebauer, Dimitrios J Richter, Petar M Seferovic, Dirk Sibbing, Giulio G Stefanini, Stephan Windecker, Rashmi Yadav, Michael O Zembala
No abstract text is available yet for this article.
January 1, 2019: European Journal of Cardio-thoracic Surgery
https://read.qxmd.com/read/30137444/management-of-antithrombotic-therapy-in-af-patients-presenting-with-acs-and-or-undergoing-pci-a-summary-of-the-joint-consensus-document-of-the-european-heart-rhythm-association-ehra-european-society-of-cardiology-working-group-on-thrombosis-european-association
#12
JOURNAL ARTICLE
https://read.qxmd.com/read/30054611/aspirin-plus-clopidogrel-vs-aspirin-alone-for-preventing-cardiovascular-events-among-patients-at-high-risk-for-cardiovascular-events
#13
JOURNAL ARTICLE
Marco P Donadini, Marta Bellesini, Alessandro Squizzato
CLINICAL QUESTION: Among patients at high risk for or with established cardiovascular disease (ie, history of peripheral artery disease, stroke, or coronary artery disease without a coronary stent), is the addition of clopidogrel to aspirin associated with lower risk of mortality and cardiovascular events compared with aspirin alone? BOTTOM LINE: Clopidogrel plus aspirin is associated with a reduced risk for myocardial infarction and ischemic stroke and an increased risk for major bleeding compared with aspirin alone among patients at high risk for or with an established cardiovascular disease but without a coronary stent...
August 14, 2018: JAMA
https://read.qxmd.com/read/29952095/beta-blockers-and-inhibitors-of-the-renin-angiotensin-aldosterone-system-for-chronic-heart-failure-with-preserved-ejection-fraction
#14
REVIEW
Nicole Martin, Karthick Manoharan, James Thomas, Ceri Davies, R Thomas Lumbers
BACKGROUND: Beta-blockers and inhibitors of the renin-angiotensin aldosterone system improve survival and reduce morbidity in people with heart failure with reduced left ventricular ejection fraction. There is uncertainty whether these treatments are beneficial for people with heart failure with preserved ejection fraction and a comprehensive review of the evidence is required. OBJECTIVES: To assess the effects of beta-blockers, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, angiotensin receptor neprilysin inhibitors, and mineralocorticoid receptor antagonists in people with heart failure with preserved ejection fraction...
June 28, 2018: Cochrane Database of Systematic Reviews
https://read.qxmd.com/read/29887195/misconceptions-in-acute-heart-failure-diagnosis-and-management-in-the-emergency-department
#15
REVIEW
Brit Long, Alex Koyfman, Eric J Chin
INTRODUCTION: Acute heart failure (AHF) accounts for a significant number of emergency department (ED) visits, and the disease may present along a spectrum with a variety of syndromes. OBJECTIVE: This review evaluates several misconceptions concerning heart failure evaluation and management in the ED, followed by several pearls. DISCUSSION: AHF is a heterogeneous syndrome with a variety of presentations. Physicians often rely on natriuretic peptides, but the evidence behind their use is controversial, and these should not be used in isolation...
September 2018: American Journal of Emergency Medicine
https://read.qxmd.com/read/29799995/aldosterone-antagonist-therapy-and-mortality-in-patients-with-st-segment-elevation-myocardial-infarction-without-heart-failure-a-systematic-review-and-meta-analysis
#16
JOURNAL ARTICLE
Khagendra Dahal, Aditya Hendrani, Sharan P Sharma, Sampath Singireddy, George Mina, Pratap Reddy, Paari Dominic, Kalgi Modi
Importance: Treatment with aldosterone antagonists is recommended and has been shown to have beneficial effects in patients with ST-segment elevation myocardial infarction (STEMI) and left ventricular ejection fraction (LVEF) less than 40%. However, the role of aldosterone antagonists in patients with ejection fraction greater than 40% or without congestive heart failure is not well known. Objectives: To perform a systematic review and meta-analysis using standard techniques to determine the role of therapy with aldosterone antagonists in this patient population...
July 1, 2018: JAMA Internal Medicine
https://read.qxmd.com/read/29850871/international-expert-consensus-document-on-takotsubo-syndrome-part-i-clinical-characteristics-diagnostic-criteria-and-pathophysiology
#17
JOURNAL ARTICLE
Jelena-Rima Ghadri, Ilan Shor Wittstein, Abhiram Prasad, Scott Sharkey, Keigo Dote, Yoshihiro John Akashi, Victoria Lucia Cammann, Filippo Crea, Leonarda Galiuto, Walter Desmet, Tetsuro Yoshida, Roberto Manfredini, Ingo Eitel, Masami Kosuge, Holger M Nef, Abhishek Deshmukh, Amir Lerman, Eduardo Bossone, Rodolfo Citro, Takashi Ueyama, Domenico Corrado, Satoshi Kurisu, Frank Ruschitzka, David Winchester, Alexander R Lyon, Elmir Omerovic, Jeroen J Bax, Patrick Meimoun, Guiseppe Tarantini, Charanjit Rihal, Shams Y-Hassan, Federico Migliore, John D Horowitz, Hiroaki Shimokawa, Thomas Felix Lüscher, Christian Templin
Takotsubo syndrome (TTS) is a poorly recognized heart disease that was initially regarded as a benign condition. Recently, it has been shown that TTS may be associated with severe clinical complications including death and that its prevalence is probably underestimated. Since current guidelines on TTS are lacking, it appears timely and important to provide an expert consensus statement on TTS. The clinical expert consensus document part I summarizes the current state of knowledge on clinical presentation and characteristics of TTS and agrees on controversies surrounding TTS such as nomenclature, different TTS types, role of coronary artery disease, and etiology...
June 7, 2018: European Heart Journal
https://read.qxmd.com/read/29724357/arrhythmias-in-patients%C3%A2-%C3%A2-80-years-of-age-pathophysiology-management-and-outcomes
#18
REVIEW
Anne B Curtis, Roshan Karki, Alexander Hattoum, Umesh C Sharma
Advances in medical care have led to an increase in the number of octogenarians and even older patients, forming an important and unique patient subgroup. It is clear that advancing age is an independent risk factor for the development of most arrhythmias, causing substantial morbidity and mortality. Patients ≥80 years of age have significant structural and electrical remodeling of cardiac tissue; accrue competing comorbidities; react differently to drug therapy; and may experience falls, frailty, and cognitive impairment, presenting significant therapeutic challenges...
May 8, 2018: Journal of the American College of Cardiology
https://read.qxmd.com/read/29674485/management-of-endocrine-disease-diagnosis-and-management-of-primary-aldosteronism-the-endocrine-society-guideline-2016-revisited
#19
REVIEW
Tracy Ann Williams, Martin Reincke
The syndrome of primary aldosteronism (PA) is characterized by hypertension with excessive, autonomous aldosterone production and is usually caused by either a unilateral aldosterone-producing adenoma or bilateral adrenal hyperplasia. The diagnostic workup of PA is a sequence of three phases comprising screening tests, confirmatory tests and the differentiation of unilateral from bilateral forms. The latter step is necessary to determine the optimal treatment approach of unilateral laparoscopic adrenalectomy (for patients with unilateral PA) or medical treatment with a mineralocorticoid receptor antagonist (for patients with bilateral PA)...
July 2018: European Journal of Endocrinology
https://read.qxmd.com/read/29688439/atrial-fibrillation-and-arrhythmias-novel-risk-assessment-proper-anticoagulation-and-ablation
#20
JOURNAL ARTICLE
Thomas F Lüscher
No abstract text is available yet for this article.
April 21, 2018: European Heart Journal
label_collection
label_collection
10771
1
2
2018-05-17 00:49:59
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.